<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of peripheral artery disease in patients with diabetes mellitus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of peripheral artery disease in patients with diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of peripheral artery disease in patients with diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berger, MD, MS, FAHA, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan D Newman, MD, MPH, FAHA, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Eidt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph L Mills, Sr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Creager, MD, FAHA, FACC, MSVM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2519033704"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>More than 170 million people worldwide have diabetes mellitus (DM), and this number is projected to increase to nearly 370 million people by 2030 [<a href="#rid1">1</a>]. DM is a major risk factor for all forms of cardiovascular disease, which is the most common cause of death for adults with DM [<a href="#rid2">2</a>]. DM is also a strong risk factor for peripheral artery disease (PAD), defined as atherosclerosis in lower extremity arteries [<a href="#rid3">3-6</a>]. Patients with DM and PAD have an increased risk of adverse cardiac and limb events and impaired quality of life [<a href="#rid7">7</a>]. Moreover, PAD causes significant long-term disability in patients with DM [<a href="#rid8">8,9</a>]. </p><p>An overview of the clinical manifestations, diagnosis, and treatment of PAD in patients with DM will be reviewed here with the goal of providing a detailed summary of this important cardiovascular phenotype, who have a high risk for vascular complications. </p><p>The manifestations of PAD in the general population, treatment, and outcomes are discussed in separate topic reviews.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/95282.html" rel="external">"Overview of lower extremity peripheral artery disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15210.html" rel="external">"Epidemiology, risk factors, and natural history of lower extremity peripheral artery disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease"</a>.)</p><p></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8215.html" rel="external">"Management of chronic limb-threatening ischemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15217.html" rel="external">"Endovascular techniques for lower extremity revascularization"</a> and  <a class="medical medical_review" href="/z/d/html/15194.html" rel="external">"Lower extremity surgical bypass techniques"</a>.)</p><p></p><p class="headingAnchor" id="H1557209976"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Peripheral artery disease (PAD) affects more than 8.5 million people in the United States, approximately one third of whom have comorbid diabetes mellitus (DM) [<a href="#rid8">8-10</a>]. The prevalence of PAD may be underestimated in the diabetic population due to the asymptomatic nature of less severe PAD and the often concomitant diabetic neuropathy [<a href="#rid9">9,11-13</a>]. (See  <a class="medical medical_review" href="/z/d/html/15210.html" rel="external">"Epidemiology, risk factors, and natural history of lower extremity peripheral artery disease"</a>.)</p><p>Even before reaching a diagnostic threshold for DM, 20 percent of patients with dysglycemia alone have an abnormal ankle-brachial index (ABI) compared with only 7 percent of patients with normal glucose homeostasis [<a href="#rid14">14</a>]. The prevalence of DM increases with age, as does the prevalence of PAD in those with, as well as those without, DM. Among individuals with DM older than 70 years of age attending outpatient medical or vascular surgery clinics in Spain, PAD was detected by screening (ABI &lt;0.90) in more than 70 percent [<a href="#rid15">15</a>]. Additionally, among patients with PAD undergoing lower extremity revascularization, approximately 50 percent have concomitant DM [<a href="#rid16">16</a>].</p><p>DM also increases the incidence of limb ischemia manifested as ischemic rest pain or ulceration among patients with PAD  (<a class="graphic graphic_figure graphicRef118241" href="/z/d/graphic/118241.html" rel="external">figure 1</a>) [<a href="#rid17">17</a>]. Among patients with DM who have chronic limb-threatening ischemia in one lower extremity, nearly one half will develop limb-threatening ischemia in the contralateral lower extremity within five years [<a href="#rid18">18</a>]. In addition to poor outcomes, patients with DM are more likely to have arterial disease distal to the knee compared with those without DM [<a href="#rid19">19,20</a>].</p><p class="headingAnchor" id="H59994961"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>DM is a powerful risk factor for PAD and is second only to cigarette smoking in contributing to the magnitude of increased risk [<a href="#rid21">21</a>]. In a large, multinational meta-analysis, the presence of DM among participants in developed countries was associated with nearly a twofold increased odds for PAD (odds ratio [OR] 1.88, 95% CI 1.66-2.14) [<a href="#rid21">21</a>]. </p><p>Advanced age, smoking, hypertension, dyslipidemia, and coronary heart disease are known risk factors for PAD. These traditional risk factors also confer significant risk for PAD among patients with DM and are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15210.html" rel="external">"Epidemiology, risk factors, and natural history of lower extremity peripheral artery disease"</a>.)</p><p class="headingAnchor" id="H2492441393"><span class="h3">Diabetes-specific</span><span class="headingEndMark"> — </span>A number of risk factors that specifically influence the occurrence of PAD in patients with DM, including diabetes duration, diabetes severity, sex, and race/ethnicity, are briefly reviewed below.</p><p class="bulletIndent1"><span class="glyph">●</span>Duration – The duration of DM correlates with the incidence and extent of PAD [<a href="#rid19">19,22</a>]. This was shown clearly among 3834 participants in the United Kingdom Prospective Diabetes Study (UKPDS 59), which showed a higher prevalence of PAD among participants with longer durations of DM [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes severity – UKPDS 59 also showed that each 1 percent increase in HbA1c was associated with nearly a 30 percent increased risk of developing PAD during follow-up (OR 1.28, 95% CI 1.12-1.46) [<a href="#rid23">23</a>]. Other measures of DM severity, such as insulin use, may also be associated with prevalent PAD [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes and patient sex – On the basis of limited data, DM appears to be a more significant risk factor for females compared with males for the development of claudication [<a href="#rid24">24</a>]. In a review of the Framingham Study Cohort, DM in the presence of glycosuria increased the risk of claudication nearly ninefold in women compared with 3.5-fold in men [<a href="#rid25">25</a>]. No confidence interval or test for heterogeneity by sex was reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes and race/ethnicity – African American and Hispanic patients with DM have a higher prevalence of PAD compared with non-Hispanic White patients, even after adjustment for other known risk factors and the excess prevalence of DM [<a href="#rid7">7,9</a>]. Reasons for these potential racial/ethnic differences in the burden of PAD among patients with DM are unknown. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PAD risk is also associated with peripheral neuropathy [<a href="#rid8">8</a>]. Thus, individuals with DM may confuse PAD symptoms with a neuropathy, a common symptom of diabetes that manifests as a burning or painful discomfort of the feet or thighs. </p><p></p><p class="headingAnchor" id="H1052975606"><span class="h3">Other risk factors</span><span class="headingEndMark"> — </span>Other risk factors associated with PAD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15210.html" rel="external">"Epidemiology, risk factors, and natural history of lower extremity peripheral artery disease"</a>.) </p><p class="headingAnchor" id="H765355386"><span class="h2">Mechanisms of increased risk</span><span class="headingEndMark"> — </span>The pathophysiology of PAD in the diabetic population is similar to that in the nondiabetic population [<a href="#rid9">9</a>] but is potentiated by the presence of concomitant DM. (See  <a class="medical medical_review" href="/z/d/html/13603.html" rel="external">"Pathogenesis of atherosclerosis"</a>.)</p><p>DM is characterized by hyperglycemia, dyslipidemia, and insulin resistance. The underlying metabolic abnormalities in DM enhance vascular inflammation, endothelial dysfunction, vasoconstriction, platelet activation, and thrombotic risk, processes important to the pathogenesis of PAD among patients with DM [<a href="#rid26">26</a>]. </p><p class="headingAnchor" id="H1120719374"><span class="h3">Increased inflammation</span><span class="headingEndMark"> — </span>Inflammation as measured by elevated levels of C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) is an established risk factor for systemic cardiovascular disease, including PAD [<a href="#rid27">27,28</a>]. DM is a hyperinflammatory state, with elevated levels of CRP and other markers of systemic inflammation [<a href="#rid29">29</a>]. Some of these inflammatory markers may also be important in PAD pathogenesis. As an example, CRP has procoagulant effects related to its enhancement of tissue factor expression [<a href="#rid30">30</a>]. Hyperglycemia from DM also leads to overproduction of mitochondrial reactive oxygen species via the protein kinase C (PKC) pathway, which in turn serves as a causal link between elevated glucose and major adverse vascular outcomes [<a href="#rid31">31</a>]. Once activated, PKC leads to structural and functional changes in the vasculature, including changes in cellular permeability, inflammation, angiogenesis, cell growth, extracellular matrix expansion, and apoptosis [<a href="#rid32">32</a>]. </p><p class="headingAnchor" id="H3584316824"><span class="h3">Endothelial dysfunction</span><span class="headingEndMark"> — </span>Endothelial dysfunction is extremely common among patients with comorbid DM and PAD. In healthy blood vessels, endothelial cells synthesize nitric oxide (NO), which is a potent vasodilator that inhibits platelet activation and vascular smooth muscle cell migration [<a href="#rid9">9</a>]. Diabetic hyperglycemia induces an imbalance between NO bioavailability and accumulation of reactive oxygen species (ROS), leading to impaired vascular health [<a href="#rid31">31,33-35</a>]. Endothelial dysfunction in diabetes is also a result of increased synthesis of vasoconstrictors and prostanoids [<a href="#rid34">34</a>]. Mitochondrial ROS production also enhances advanced glycation end product (AGE) and AGE receptor (RAGE) signaling [<a href="#rid31">31,36</a>], in turn activating ROS-sensitive biochemical pathways that further induce endothelial dysfunction and vascular homeostasis [<a href="#rid36">36,37</a>]. </p><p class="headingAnchor" id="H266051476"><span class="h3">Enhanced vasoconstriction</span><span class="headingEndMark"> — </span>Enhanced protein kinase C (PKC) activity also leads to increased production of endothelin-1 (ET-1), leading to enhanced vasoconstriction and platelet aggregation [<a href="#rid32">32</a>]. Notably, endogenous ET-1 has enhanced vascular activity among patients with type 2 DM [<a href="#rid38">38</a>]. In the setting of diabetic hyperglycemia, increased PKC activity alters NO signaling and enhances vasoconstriction [<a href="#rid31">31</a>], two processes important in the pathogenesis of PAD [<a href="#rid39">39</a>]. </p><p class="headingAnchor" id="H1436016128"><span class="h3">Enhanced thrombosis</span><span class="headingEndMark"> — </span>Among patients with DM, insulin resistance and hyperglycemia contribute to a prothrombotic state, characterized by increased platelet activation and coagulation [<a href="#rid40">40,41</a>]. </p><p>Insulin resistance increases levels of plasminogen activator inhibitor-1 (PAI-1) and fibrinogen. Patients with DM and poor glycemic control have high levels of PAI-1, and some studies have suggested that treatment with glucose-lowering agents such as <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a> and <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> decrease levels of PAI-1 [<a href="#rid42">42</a>]. In addition, hyperinsulinemia and hyperglycemia can act synergistically to increase monocyte expression of tissue factor, increasing procoagulant activity and thrombin generation [<a href="#rid43">43,44</a>]. </p><p>Microparticles, which are vesicles released in the circulation from various cell types in response to apoptosis or activation, are increased in patients with DM and independently predict cardiovascular events in patients with stable coronary heart disease [<a href="#rid45">45</a>]. Microparticles also increase coagulant activity in the endothelial cells of patients with DM and promote thrombus formation at sites of injury [<a href="#rid46">46</a>]. Increased platelet-derived microparticles are also associated with PAD and may represent a pathway of shared pathogenesis for PAD risk among patients with DM [<a href="#rid47">47</a>]. </p><p>Finally, platelet hyperreactivity likely has major relevance for macrovascular disease and PAD in those with DM. A number of mechanisms contribute to platelet dysfunction and hyperreactivity in DM [<a href="#rid31">31</a>], many of which may also play a role in the pathogenesis of PAD [<a href="#rid47">47</a>]. Hyperglycemia alters platelet-calcium homeostasis and increases secretion of factors that increase platelet aggregability [<a href="#rid48">48</a>]. Upregulation of glycoproteins Ib and IIb/IIIa among patients with DM interacts with von Willebrand factor and fibrin to trigger thrombogenesis [<a href="#rid31">31</a>]. </p><p class="headingAnchor" id="H288548304"><span class="h1">CLINICAL MANIFESTATIONS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The clinical manifestations of lower extremity atherosclerotic vascular disease (ie, peripheral artery disease [PAD]), which include claudication, rest pain, ulceration, and gangrene, are predominantly due to progressive luminal narrowing (stenosis/occlusion), although thrombosis or embolism of unstable atherosclerotic plaque or material can also occur. (See  <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a> and  <a class="medical medical_review" href="/z/d/html/8184.html" rel="external">"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"</a> and  <a class="medical medical_review" href="/z/d/html/8197.html" rel="external">"Thromboembolism from aortic plaque"</a>.)</p><p>Single-level disease (ie, aortoiliac, superficial femoral) often manifests initially as claudication. Multilevel disease can also manifest as claudication, provided that sufficient collateral circulation develops. Some [<a href="#rid49">49</a>], but not all [<a href="#rid19">19</a>], studies suggested that patients with diabetes mellitus (DM) and PAD are less likely to present with typical claudication symptoms. While it may be challenging to discern differences in PAD symptomatology in patients with versus without DM, patients with DM tend to present with more advanced disease and have a worse prognosis. As an example, the rates of foot ulcers and lower extremity amputations are higher in PAD patients with DM compared with those who do not have DM [<a href="#rid49">49,50</a>]. In addition to presenting with more advanced disease, there may be anatomic differences in the vascular distribution of PAD that contribute to a worse prognosis. DM may be associated with more severe below-the-knee PAD (eg, popliteal, anterior tibial, peroneal, and posterior tibial) [<a href="#rid8">8,19</a>]. By comparison, risk factors such as smoking are associated with more proximal PAD in the aortoiliofemoral vessels.</p><p>It has also been reported that patients with PAD and comorbid DM experience worse lower extremity function compared with those with PAD alone [<a href="#rid49">49</a>]. Impaired lower extremity functioning is an important predictor of future disability, including mobility loss and nursing home placement. Thus, the patient with DM and PAD is a high-risk clinical phenotype who should be evaluated for comorbidities such as neuropathy, foot ulceration, or concomitant coronary heart disease that could contribute to disability [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H632678465"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>In patients with DM, a thorough history of physical activity will frequently identify patients with PAD risk factors or preexisting PAD. However, symptoms of leg pain, the development of ulcers, and functional impairments can be due to PAD or can be manifestations of diabetic neuropathy [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/5272.html" rel="external">"Screening for diabetic polyneuropathy"</a>.)</p><p>For patients with an appropriate history and physical examination, the diagnosis of PAD is established with the measurement of the ankle-brachial index (ABI) [<a href="#rid51">51</a>]. The ABI is a comparison of the higher posterior tibial or dorsalis pedis systolic blood pressure in each leg divided by the higher of the right or left arm systolic blood pressure (SBP) [<a href="#rid51">51</a>]. An ABI ≤0.90 is sensitive and specific for arterial stenosis and is diagnostic for PAD [<a href="#rid52">52</a>], though additional testing may be warranted for patients with DM. For patients with appropriate symptoms and a normal ABI, an ABI following exercise testing may provide additional information. (See  <a class="medical medical_review" href="/z/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Ankle-brachial index'</a> and  <a class="medical medical_review" href="/z/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Exercise testing'</a> and  <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease", section on 'Diagnosis of lower extremity PAD'</a>.)</p><p>DM and other comorbid conditions such as chronic kidney disease may lead to calcification of the arterial wall, which can make the ankle artery incompressible and limit the measurement of systolic pressure at that location in spite of blood pressure cuff inflation even as high as 250 mmHg [<a href="#rid51">51</a>]. It is important to remember that vascular wall calcification does not imply that occlusive arterial disease is present, although these two conditions frequently coexist. However, when vascular calcification is present, stenotic vascular disease cannot be detected by ABI [<a href="#rid53">53,54</a>]. In this setting, other noninvasive tests such as measurement of the toe-brachial index (TBI) or Doppler waveform analysis may enable detection of occlusive disease despite a falsely elevated ABI [<a href="#rid51">51</a>]. Measurement of the TBI is useful in this setting because the digital vessels rarely develop calcification and can provide an accurate determination of vascular disease in the presence of vascular calcification [<a href="#rid53">53,54</a>]. (See  <a class="medical medical_review" href="/z/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Toe-brachial index'</a>.)</p><p class="headingAnchor" id="H3225156142"><span class="h2">Screening</span><span class="headingEndMark"> — </span>Many patients with DM and PAD have symptoms, which may be typical or atypical. In these situations, formal ABI testing is required to diagnose PAD [<a href="#rid55">55</a>]. Measuring an ABI among patients with DM and typical intermittent claudication or atypical lower extremity symptoms is endorsed in a white paper from the American Heart Association and a position statement from the American Diabetes Association [<a href="#rid8">8,51</a>]. There should be a very low threshold to obtain vascular studies in patients who develop any lower extremity symptoms that may be consistent with PAD, such as atypical leg pain or claudication, and it is mandatory in those with wounds that are slow to heal to determine whether arterial disease is a contributing factor  (<a class="graphic graphic_algorithm graphicRef103017" href="/z/d/graphic/103017.html" rel="external">algorithm 1</a>) [<a href="#rid3">3,56</a>]. (See  <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease", section on 'Diagnosis of lower extremity PAD'</a>.)</p><p>The use of screening ABI among patients with DM without any symptoms or wound problems is controversial. There are no randomized trials comparing PAD screening versus no screening solely in DM [<a href="#rid57">57</a>]. The American Diabetes Association has recommended that a screening ABI should be performed in patients &gt;50 years of age with DM and, if normal, should be repeated every five years [<a href="#rid8">8</a>]. The guideline further recommends consideration of screening ABI in patients with DM age &lt;50 years with other PAD risk factors, such as smoking, hypertension, hyperlipidemia, or diabetes duration &gt;10 years [<a href="#rid8">8</a>]. The American College of Cardiology/American Heart Association guidelines state that screening for PAD by ABI is reasonable among asymptomatic individuals over age 50 with DM, or less than age 50 with one additional cardiovascular disease risk factor, or who have known atherosclerosis in another vascular bed [<a href="#rid3">3,58</a>]. These broad screening criteria are considered justifiable given the noninvasive nature of ABI testing and the high prevalence of abnormal resting ABIs in asymptomatic high-risk patients, such as diabetes [<a href="#rid58">58-61</a>]. By contrast, the US Preventive Services Task Force Recommendation Statement suggested that since patients with DM or known risk factors or cardiovascular disease are already at high risk for cardiovascular disease (CVD) events, screening for PAD with an ABI is unlikely to alter effective management decisions and improve clinical outcomes [<a href="#rid62">62</a>]. </p><p class="headingAnchor" id="H486665085"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of patients with diabetes mellitus (DM) and peripheral artery disease (PAD) is similar to the management of patients with PAD without DM and is focused on relieving symptoms and lowering the risk of cardiovascular disease progression and complications. This will necessarily take into account managing comorbid DM and other medical comorbidities, compliance with pharmacologic treatments and follow-up care, along with the subjective values and goals of the individual patient. </p><p class="headingAnchor" id="H2058969497"><span class="h2">Risk factor modification</span><span class="headingEndMark"> — </span>PAD and DM are both regarded as risk equivalents for coronary heart disease. We agree with major cardiovascular practice guidelines for the management of both DM and PAD (asymptomatic or symptomatic) that recommend secondary prevention strategies to reduce the risk of future cardiovascular events for patients with either DM or PAD [<a href="#rid58">58,63</a>]. </p><p>An aggressive approach to risk factor modification is warranted in patients with diabetes and PAD. A subgroup analysis of the Effects of <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">Ticagrelor</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> in Patients with Peripheral Artery Disease (EUCLID) trial evaluated outcomes in 5345 patients with diabetes (mostly type 2) and PAD compared with PAD alone [<a href="#rid64">64,65</a>]. Patients with PAD and diabetes had a higher composite risk of major adverse cardiovascular events (MACE; cardiovascular death, myocardial infarction, and ischemic stroke), all-cause mortality, and adverse limb events in spite of risk reduction therapies, including statins, blood pressure–lowering medications, and antiplatelet therapy. The risk for major amputation was increased by 96 percent, the risk for lower extremity revascularization was increased by 25 percent, and the risk for carotid revascularization was increased by 35 percent. Each 1 percent increase in glycated hemoglobin (HbA1c) increased the risk for MACE by 14 percent. However, the association between HbA1c and major amputation was not statistically significant.</p><p>Domains of risk factor modification to improve PAD outcomes and reduce risk of incident cardiovascular disease risk include smoking cessation, antiplatelet therapy, lipid-lowering therapy, blood pressure control, diet and exercise, as well as care of the foot and lower extremity. These domains of risk factor modification are relevant for all patients with PAD. (See  <a class="medical medical_review" href="/z/d/html/95282.html" rel="external">"Overview of lower extremity peripheral artery disease", section on 'Risk factor modification'</a>.)</p><p>We will focus herein on data supporting practices to improve PAD and coronary heart disease outcomes for patients with comorbid DM and PAD. </p><p class="headingAnchor" id="H2211834762"><span class="h3">Smoking cessation</span><span class="headingEndMark"> — </span>We agree with consensus guidelines that recommend smoking cessation for all PAD patients [<a href="#rid58">58</a>] and believe these recommendations also apply to patients with both PAD and DM. Numerous epidemiological and observational studies have shown that smoking cessation reduces adverse cardiovascular events and the risk for limb loss in patients with PAD. Tobacco use is a strong risk factor for the development and progression of PAD [<a href="#rid66">66</a>]. There is also evidence that among patients with a recent myocardial infarction, the benefits of smoking cessation were similar for those with and without DM [<a href="#rid67">67</a>]. Data have also shown that weight gain associated with smoking cessation, even among patients with DM, does not significantly attenuate the reduction in cardiovascular risk observed with smoking cessation [<a href="#rid68">68</a>].</p><p>Patients with PAD who smoke cigarettes should be assisted in developing a plan for quitting that includes pharmacotherapy (<a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, and/or <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement) and/or referral to a smoking cessation program. In a trial of 124 probable smokers with PAD, participants randomly assigned to receive PAD-specific smoking cessation counseling were more likely to be confirmed abstinent at six months than participants assigned to usual care (21.3 versus 6.8 percent) [<a href="#rid69">69</a>]. Two meta-analyses of randomized trials of smoking cessation medications showed no evidence of increased cardiovascular event rates with nicotine replacement, bupropion, or varenicline [<a href="#rid70">70,71</a>]. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults"</a>.)</p><p class="headingAnchor" id="H2213373642"><span class="h3">Antithrombotic therapy</span><span class="headingEndMark"> — </span>Based upon randomized trials demonstrating a reduction in incident cardiovascular events, we agree with major cardiovascular consensus guidelines recommending long-term antiplatelet therapy for patients with symptomatic lower extremity PAD [<a href="#rid58">58</a>]. Similarly, we also agree with recommendations for long-term antiplatelet therapy for patients with diabetes mellitus (DM) age ≥50 years with risk factors for cardiovascular disease (CVD) or younger DM patients with prior CVD [<a href="#rid26">26,72</a>]. We do not routinely recommend the use of dual antiplatelet therapy for patients with DM and PAD in the absence of other indications (eg, drug-eluting stent) given the increase in bleeding and the absence of proven benefit.</p><p>In a meta-analysis of 18 trials comprising nearly 5300 patients with PAD (symptomatic and asymptomatic), <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy alone or in combination with <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> was associated with nonsignificant reduction in the primary endpoint (composite of nonfatal myocardial infarction [MI], nonfatal stroke, and cardiovascular death) but a significant reduction in the secondary outcome of nonfatal stroke (relative risk [RR] 0.66; 95% CI 0.47-0.94) [<a href="#rid73">73</a>]. There have been two randomized trials of aspirin that predominantly enrolled patients with PAD and DM: one was limited to patients with DM and asymptomatic PAD [<a href="#rid74">74</a>], and in the other (Critical Leg Ischemia Prevention Study [CLIPS]), a majority of trial participants (approximately 80 percent) had symptomatic PAD [<a href="#rid75">75</a>]. Aspirin treatment was not associated with a benefit in patients with DM and asymptomatic PAD [<a href="#rid74">74</a>]. The CLIPS trial demonstrated a benefit of aspirin (100 mg daily) compared with placebo for preventing vascular events, but the study was too small to derive meaningful conclusions [<a href="#rid58">58,75</a>]. The use of other antiplatelet agents (<a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>, <a class="drug drug_general" data-topicid="95242" href="/z/d/drug information/95242.html" rel="external">vorapaxar</a>) for use in the general PAD population is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/95282.html" rel="external">"Overview of lower extremity peripheral artery disease", section on 'Antithrombotic therapy'</a>.)</p><p>The evidence to support the use of these agents among patients with DM and PAD is summarized as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>In the <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> Versus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> in Patients at Risk of Ischemic Events (CAPRIE) trial, clopidogrel (75 mg/day) had a modest but significant benefit over aspirin (325 mg/day) for reducing the risk of the combined outcome of ischemic stroke, myocardial infarction (MI), or vascular death among patients with a recent stroke, MI, or symptomatic PAD [<a href="#rid76">76</a>]. The benefit of clopidogrel was driven largely by the subgroup of patients with PAD [<a href="#rid76">76</a>]. Among the 19,185 patients in CAPRIE, there were 3866 patients with DM. Subgroup analyses suggested that patients with DM in CAPRIE, and particularly those DM receiving insulin, derived a greater benefit from clopidogrel than from aspirin for the trial composite outcome plus rehospitalization for ischemia or bleeding [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the PEGASUS-TIMI 54 trial, 21,162 patients with an MI one to three years prior to enrollment were randomly assigned to <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> 60 or 90 mg twice daily or placebo, all on a background of low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid78">78</a>]. Among PAD patients with prior MI (1142 patients, 5 percent of total), ticagrelor significantly reduced the absolute rate of major adverse cardiovascular events (MACE) by 4.1 percent. The 90 mg dose of ticagrelor also significantly reduced the risk of peripheral revascularization (hazard ratio [HR] 0.63, 95% CI 0.43-0.93). However, a 0.12 percent absolute excess of major bleeding with ticagrelor was also observed [<a href="#rid79">79</a>]. Subgroup analyses of patients with DM in PEGASUS also demonstrated reductions in the primary endpoint with the use of ticagrelor. As patients with DM were at higher risk of MACE compared with participants without DM, the absolute risk reduction with ticagrelor tended to be greater in patients with DM (absolute risk reduction of 1.9, 1.5, and 1.1 percent for patients with DM requiring medication, all DM patients, and patients without DM, respectively) [<a href="#rid80">80</a>]. The benefits of ticagrelor on major adverse limb events (MALE) was observed in the Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS trial) which examined DAPT (dual antiplatelet therapy) with ticagrelor in patients with diabetes and coronary disease [<a href="#rid81">81</a>]. In THEMIS, 1687 participants had concomitant CAD and PAD. Dual antiplatelet therapy with aspirin and ticagrelor had a consistent reduction in MACE for participants with DM and CAD, with and without concomitant PAD, and showed an approximately 50 percent reduction in MALE for the overall study population (HR 0.45, 95% CI 0.23-0.86). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="95242" href="/z/d/drug information/95242.html" rel="external">Vorapaxar</a> is a novel antagonist of protease-activated receptor (PAR-1), which is located on platelets, vascular endothelium, and smooth muscle and is the primary receptor for thrombin on human platelets [<a href="#rid82">82</a>]. In the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients with Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50), among patients with symptomatic PAD, vorapaxar reduced the rate of first acute limb ischemia events, particular among those with prior revascularization [<a href="#rid83">83-85</a>]. There was also limited evidence that patients with DM and a prior MI were more likely to benefit from PAR-1 antagonism than MI patients without DM [<a href="#rid86">86</a>]. Data are lacking on prespecified comparisons of vorapaxar use among PAD patients with versus without DM. However, since DM is associated with a fourfold increase in limb-threatening ischemia [<a href="#rid17">17</a>], and vorapaxar may reduce the rate of first acute limb ischemia [<a href="#rid83">83</a>], PAR-1 antagonism may be a useful therapeutic option for patients with DM and PAD. </p><p></p><p>Whether there is a benefit for other anticoagulant formulations versus antiplatelet therapy for patients with DM and PAD has not been established [<a href="#rid87">87,88</a>]. For the overall PAD population, routine anticoagulation using <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> in addition to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> does <strong>not</strong> reduce cardiovascular events including mortality and is associated with an increase in life-threatening bleeding [<a href="#rid89">89</a>]. There is a paucity of data on the use of warfarin in addition to aspirin for patients with DM and PAD. </p><p>Data suggest a benefit for combined <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and low-dose <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> (a direct oral anticoagulant) for individuals with PAD, including those with DM, although with an increased risk for bleeding. A multicenter international trial randomly assigned over 27,000 patients with stable coronary heart disease or PAD to a low dose of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily), rivaroxaban (5 mg twice daily) plus placebo, or aspirin (100 mg daily) plus placebo [<a href="#rid87">87</a>]. At a mean follow-up of 23 months, rivaroxaban plus aspirin significantly reduced cardiovascular mortality and ischemic stroke compared with aspirin alone. In a prespecified subgroup analysis among nearly 7500 participants with PAD, rivaroxaban plus aspirin reduced the composite of cardiovascular death, myocardial infarction, or stroke compared with aspirin alone (HR 0.72, 95% CI 0.57-0.90) along with major adverse limb events (1 versus 2 percent; HR 0.54, 95% CI 0.35-0.82) [<a href="#rid88">88</a>]. This benefit was similar for PAD patients with DM (HR 0.69, 95% CI 0.53-0.91) compared with those without DM (HR 0.69, 95% CI 0.50-0.94). </p><p>In another large international trial, 6564 patients with symptomatic PAD who underwent successful lower extremity revascularization within the preceding 10 days were randomly assigned to <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> 2.5 mg twice daily plus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or placebo plus aspirin (VOYAGER-PAD) [<a href="#rid90">90</a>]. Approximately 40 percent of patients in VOYAGER-PAD trial had DM. <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> could be administered for up to six months after revascularization at the discretion of the investigator and was used in 51 percent of participants at baseline. At a median of 28 months of follow-up (interquartile range 22 to 34), use of rivaroxaban plus aspirin significantly reduced the primary efficacy outcome (composite outcome of acute limb ischemia, major amputation for vascular causes, stroke, myocardial infarction or cardiovascular death) compared with placebo plus aspirin (17.3 versus 19.9 percent; HR 0.85, 95% CI 0.79-0.96). There was no observed heterogeneity of treatment effect with rivaroxaban for participants with compared to without diabetes mellitus. While the incidence of thrombolysis in myocardial infarction major bleeding did not differ between groups, the incidence of International Society on Thrombosis and Haemostasis bleeding was significantly higher with rivaroxaban and aspirin than with aspirin alone (6 versus 4 percent; HR 1.42, 95% CI 1.10-1.84). </p><p class="headingAnchor" id="H261802710"><span class="h3">Lipid-lowering therapy</span><span class="headingEndMark"> — </span>Lipid-lowering therapy with at least a moderate dose of high-intensity statin, regardless of baseline low-density lipoprotein (LDL) cholesterol, is recommended for all patients with atherosclerotic cardiovascular disease [<a href="#rid91">91</a>]. The evidence for benefit and the appropriate goals for cholesterol lowering in patients with all forms of cardiovascular disease are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p>Examples of a reduction in cardiovascular outcomes with the use of statin therapy among patients with PAD include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Among nearly 6800 participants in the Heart Protection Study with PAD, there was a 22 percent relative risk reduction in a first major vascular event for those randomized to <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> 40 mg compared with placebo [<a href="#rid92">92</a>]. The absolute reduction in first major vascular event was 63 (standard error [SE] 11) per 1000 patients with PAD and 50 (SE 7) per 1000 without preexisting PAD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite guidelines recommending high-intensity statin use for all adults with apparent atherosclerotic cardiovascular disease [<a href="#rid91">91</a>], evidence was lacking to support the use of high-intensity statins for patients with PAD. An observational cohort analysis from the Veterans Health Administration found that high-intensity statin use at the time of PAD diagnosis is associated with significant reduction in limb loss and mortality in comparison with low-to-moderate-intensity statin users [<a href="#rid93">93</a>]. In this population, the benefit associated with high-intensity statin use was similar for patients with PAD with and without DM [<a href="#rid93">93</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar findings for a reduction in limb loss and mortality with high-intensity statin use were observed in a study of patients with chronic limb-threatening ischemia [<a href="#rid94">94</a>]. In this retrospective study of 931 patients (1019 affected limbs) undergoing first-time revascularization (endovascular or surgical), high-intensity statin therapy was associated with lower mortality (HR 0.73, 95% CI 0.60-0.99) and lower rate of major adverse limb events (HR 0.71, 95% CI 0.51-0.97) compared with PAD patients receiving lower-intensity dose statins.</p><p></p><p>There is also robust evidence for cardiovascular risk reduction with statins, including high-intensity dosing, for patients with DM with and without preexisting cardiovascular disease [<a href="#rid95">95-97</a>]. Thus, we suggest that all patients with PAD and DM should be treated with the maximum tolerated dose of a high-intensity statin (eg, <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> 20 to 40 mg, <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> 40 to 80 mg daily) [<a href="#rid91">91</a>]. (See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Lipid management'</a>.)</p><p>Finally, there are emerging data that lipid lowering with <a class="drug drug_general" data-topicid="103780" href="/z/d/drug information/103780.html" rel="external">evolocumab</a>, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, may be highly beneficial for patients with PAD [<a href="#rid98">98</a>]. FOURIER was a randomized trial of evolocumab versus placebo in 27,564 patients with established atherosclerotic disease on statin therapy that demonstrated a significant reduction in a composite cardiovascular outcomes compared with placebo over 2.2 years [<a href="#rid99">99</a>]. A prespecified secondary analysis of the 3642 patients with PAD at baseline (1505 with no prior myocardial infarction or stroke) demonstrated consistent reductions in the primary composite outcome (cardiovascular death, myocardial infarction, stroke, admission for unstable angina, or coronary revascularization) associated with the use of evolocumab among patients with PAD (HR 0.79, 95% CI 0.66-0.94) and without PAD (HR 0.86, 95% CI 0.80-0.93) [<a href="#rid98">98</a>]. In addition to significant reductions in the key secondary endpoint of cardiovascular death, myocardial infarction, or stroke, evolocumab reduced the risk of major adverse limb events in all patients (HR 0.58, 95% CI 0.38-0.88) with consistent effects in those with and without known PAD [<a href="#rid98">98</a>]. This analysis from FOURIER demonstrated that the addition of a non-statin low-density lipoprotein cholesterol (LDL-C) lowering to statin therapy reduces major adverse limb events in patients with symptomatic PAD, along with patients with symptomatic coronary or cerebrovascular disease, and that the benefits on lower extremity vasculature extend to very low achieved LDL-C [<a href="#rid98">98</a>]. </p><p>In one other study of non-statin lipid-lowering treatment with <a class="drug drug_general" data-topicid="91482" href="/z/d/drug information/91482.html" rel="external">fenofibrate</a> versus placebo among individuals with type 2 DM and PAD, prior amputation or neuropathy demonstrated a significant 36 percent reduction in amputations over five years, likely via non-LDL-C mechanisms [<a href="#rid100">100</a>]. </p><p class="headingAnchor" id="H3505449842"><span class="h3">Glycemic control</span><span class="headingEndMark"> — </span>Although it is unknown whether aggressive serum glucose control decreases the likelihood of adverse cardiovascular events among patients with PAD and DM, treatment of DM can be effective for reducing complications. We agree with recommendations for control of blood glucose levels with an HbA1c goal &lt;7.0 percent [<a href="#rid101">101</a>]. Less stringent goals may be appropriate for some patients (eg, older patients, and those with multiple comorbid medical conditions). (See  <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus"</a>.)</p><p>Cardiovascular outcomes trials with two new classes of agents, the sodium-glucose co-transporter 2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP1-RA), have demonstrated reductions in cardiovascular events, including mortality, primarily for patients with DM and cardiovascular disease. In preclinical models, GLP1-RAs lowered vascular expression of proinflammatory pathways, improved endothelial function, and inhibited platelet aggregation and atherosclerosis [<a href="#rid102">102-104</a>]. GLP1-RAs lower glucose through a different mechanism. Cardiovascular outcomes trials for both SGLT2-i [<a href="#rid105">105,106</a>] and GLP1-RA [<a href="#rid107">107,108</a>] have included DM patients with PAD. (See  <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus"</a>.)</p><p>Cardiovascular outcomes and the safety of SGT2-i use among DM patients with PAD has proven to be of particular interest. </p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">CANagliflozin</a> cardioVascular Assessment Study (CANVAS) Program identified safety concerns for amputations, collected as an adverse event of special interest (HR 1.97, 95% CI 1.41-2.75), and fractures (any fracture HR 1.26, 95% CI 1.04-1.52) [<a href="#rid106">106,109</a>]. The amputations in the CANVAS program were primarily below the ankle (ie, toe, transmetatarsal amputation) and occurred more often in those with a prior history of PAD or prior amputation. Similar findings were observed in a population-based cohort study involving over 25,000 patients with type 2 DM from the United States Department of Defense Military Health System [<a href="#rid110">110</a>]. The authors observed a consistent twofold risk of below-the-knee amputation, with the greatest absolute risk occurring among patients with established PAD [<a href="#rid111">111,112</a>]. Canagliflozin was used in 58.1 percent of patients in this study, with 26.4 and 15.5 percent on <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a> and <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a>, respectively [<a href="#rid110">110</a>]. As this study was not powered to make comparisons among individual treatments, it could not evaluate whether below-the-knee amputation risk extended across the SGLT2-i medication class. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data from other SGLT2 inhibitor cardiovascular outcome trials have not indicated an increased risk of amputation [<a href="#rid113">113-116</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Results from the <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">Canagliflozin</a> and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, also evaluating canagliflozin versus placebo, did not show an increased risk of amputation among 4401 participants with DM and albuminuric chronic kidney disease with an estimated glomerular filtration rate of 30 to &lt;90 mL per minute per 1.73 m<sup>2</sup> [<a href="#rid113">113</a>]. Approximately 24 percent of participants in CREDENCE had a clinical diagnosis of PAD at baseline. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In addition, among the 1461 participants with PAD at baseline in EMPA-REG, <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a> had consistent, significant reductions in cardiovascular and all-cause mortality, along with composites of major adverse cardiovascular outcomes [<a href="#rid114">114</a>]. There was no significant difference in any or major amputations for patients receiving empagliflozin compared with placebo among patients with or without PAD at baseline. There was also no increase in the risk of amputation observed with <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a> compared to placebo in The Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction (DECLARE-TIMI) 58 [<a href="#rid115">115</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar findings were observed when the use of <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a> was examined among patients with and without PAD in DECLARE-TIMI 58 [<a href="#rid116">116</a>]. Among the 17,160 patients with DM and cerebrovascular disease included in DECLARE-TIMI 58, 1025 (6 percent) had PAD. Compared with those without PAD, participants with PAD were at higher risk for adverse events including cardiovascular death, heart failure, and progression of kidney disease. Participants with versus without PAD were at higher risk for major adverse limb events, there were no significant differences in any ischemic limb adverse events with dapagliflozin versus placebo with no significant interaction by history of PAD.</p><p></p><p>The observed effects on vascular function and platelet aggregation from preclinical studies may translate into the benefits for ischemic outcomes for GLP1-RA [<a href="#rid107">107,108</a>]. Ongoing studies are evaluating whether the vascular effects of GLP1-RA translate into improved functional outcomes for patients with PAD and diabetes (NCT04560998). </p><p class="bulletIndent1"><span class="glyph">●</span>Post-hoc subgroup analysis from the <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">Liraglutide</a> Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER trial) showed that liraglutide significantly reduces the risk of amputation by approximately 35 percent (HR 0.65, 95% CI 0.45-0.95) [<a href="#rid117">117</a>]. Further outcomes come from an analysis of patients with DM and PAD receiving placebo or either liraglutide or <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">semaglutide</a>, respectively, from LEADER and Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6). Overall, 1184/9340 (12.7 percent) patients in LEADER and 460/3297 (14 percent) in SUSTAIN 6 had DM and comorbid PAD at baseline. The effects of both therapies on MACE appeared beneficial in patients with PAD. The absolute risk reduction for MACE was higher for patients with DM with compared to without comorbid PAD [<a href="#rid118">118</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the <a class="drug drug_general" data-topicid="9005" href="/z/d/drug information/9005.html" rel="external">Exenatide</a> Study of Cardiovascular Event Lowering (EXSCEL trial [<a href="#rid119">119</a>]), there were 2800/14,752 (18.9 percent) with PAD at baseline. Patients with DM and comorbid PAD in EXSCEL had a higher adjusted hazard ratio ([aHR] 1.13, 95% CI 1.00-1.27) for MACE compared with patients without PAD. Patients with DM and PAD in EXSCEL more frequently underwent lower extremity amputation (aHR 5.48, 95% CI 4.16-7.22). However, patients treated with exenatide or placebo had similar rates of MACE and lower extremity amputation, regardless of PAD status [<a href="#rid120">120</a>]. </p><p></p><p class="headingAnchor" id="H3593101806"><span class="h3">Antihypertensive therapy</span><span class="headingEndMark"> — </span>Hypertension is a major risk factor for PAD. We agree with current PAD guidelines that target blood pressure, and selection of antihypertensive therapy should be consistent with current published guidelines for hypertension management [<a href="#rid58">58,121</a>].</p><p>Concerns have been raised that antihypertensive therapy may worsen limb perfusion. However, a number of studies have demonstrated that blood pressure treatment, including the use of beta blockers, does not appear to worsen claudication or impair functional status for patients with PAD [<a href="#rid122">122,123</a>]. </p><p>The Ongoing <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">Telmisartan</a> Alone and in Combination with <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">Ramipril</a> Global Endpoint (ONTARGET) trial was a study that compared telmisartan, ramipril, and combination therapy in patients with cardiovascular disease, including PAD and/or DM. The efficacy of telmisartan was similar in the 3468 patients with PAD and for patients with and without DM [<a href="#rid124">124</a>].</p><p class="headingAnchor" id="H914208677"><span class="h3">Diet and exercise</span><span class="headingEndMark"> — </span>Healthy diets are associated with lower cardiovascular disease events. Guidelines from the American Heart Association/American College of Cardiology (AHA/ACC) and European Society of Cardiology (ESC) on lifestyle management are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p>Lifestyle management is also crucial for reducing vascular risk among patients with DM. (See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease", section on 'Exercise therapy'</a>.)</p><p class="headingAnchor" id="H2339029879"><span class="h2">Evaluation and care of the diabetic foot</span><span class="headingEndMark"> — </span>Foot problems are an important cause of morbidity and mortality in patients with DM. Evaluation of the diabetic foot may also reveal underlying PAD and prompt earlier diagnosis and management. These issues are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1749.html" rel="external">"Evaluation of the diabetic foot"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7651.html" rel="external">"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8175.html" rel="external">"Management of diabetic foot ulcers"</a>.)</p><p></p><p class="headingAnchor" id="H422153505"><span class="h1">REVASCULARIZATION</span><span class="headingEndMark"> — </span>Revascularization, either via a surgical or endovascular approach, is an important therapeutic option for treatment of symptomatic peripheral artery disease (PAD) in patients with diabetes mellitus (DM) [<a href="#rid9">9</a>]. The overall volume of endovascular procedures has increased significantly among patients with DM and foot ulcer, while open surgical bypass has decreased [<a href="#rid125">125</a>]. Among patients undergoing lower extremity revascularization, prevalent DM is an independent risk factor for major limb amputation and six-month hospital readmission [<a href="#rid16">16</a>].</p><p>Overall strategies for revascularization in patients with PAD are discussed in detail separately. Based upon the available data comparing outcomes in patients with and without DM, there does not appear to be any obvious subset of patients with DM for whom revascularization strategies should differ. Medical optimization including control of cardiovascular risk factors and glycemic control is important prior to revascularization. (See  <a class="medical medical_review" href="/z/d/html/95282.html" rel="external">"Overview of lower extremity peripheral artery disease", section on 'Revascularization'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease"</a> and  <a class="medical medical_review" href="/z/d/html/15220.html" rel="external">"Approach to revascularization for claudication due to peripheral artery disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8215.html" rel="external">"Management of chronic limb-threatening ischemia"</a>.)</p><p></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15217.html" rel="external">"Endovascular techniques for lower extremity revascularization"</a> and  <a class="medical medical_review" href="/z/d/html/15194.html" rel="external">"Lower extremity surgical bypass techniques"</a>.)</p><p></p><p class="headingAnchor" id="H3788598147"><span class="h2">Patency</span><span class="headingEndMark"> — </span>Most data for surgical bypass (vein conduit) show no difference in patency between those with and without diabetes; however, for endovascular therapy, DM has an adverse impact on patency [<a href="#rid126">126-131</a>]. </p><p>Reduced patency rates may, in part, be due to the more distal distribution disease in patients with DM and PAD, which tends to be more severe in arterial vessels below the knee, and which can be difficult to access from an endovascular approach. This finding may also be due to the quality of runoff. In a review of 127 iliac and femoropopliteal angioplasties, among patients with good runoff, patency rates were comparable to those without DM [<a href="#rid132">132</a>]. </p><p>The relationship between glycemic control and lower extremity patency after revascularization has been evaluated, but data remain limited. A single-center, retrospective study divided patients with DM undergoing infrapopliteal balloon angioplasty into two groups based on median preprocedure fasting blood glucose (FBG) [<a href="#rid133">133</a>]. At one year of follow-up, freedom from restenosis or reintervention was significantly lower for those with FBG above versus below median FBG values (16 versus 46 percent) [<a href="#rid133">133</a>]. Amputation rates also trended higher among patients with high preprocedure FBG compared with low FBG. </p><p>The prevalence of DM among patients with limb-threatening ischemia is extremely high, with some estimating a prevalence over 75 percent, and it will usually require revascularization [<a href="#rid9">9</a>]. Data suggest that surgical and endovascular approaches with percutaneous transluminal angioplasty (PTA), with or without stenting, are associated with similar outcomes with regard to amputation-free survival or repeated target extremity revascularization [<a href="#rid134">134</a>]. Additional studies have shown that patients with DM and chronic limb-threatening ischemia treated with an aggressive multidisciplinary approach have limb salvage outcomes similar to the patients without DM [<a href="#rid135">135</a>]. </p><p class="headingAnchor" id="H566237742"><span class="h2">Amputation</span><span class="headingEndMark"> — </span>A program of preventive foot care and intervention when needed (eg, infection drainage, podiatric surgery, revascularization) can help prevent many major amputations. However, for some, amputation may represent an acceptable option for patients with a prolonged course of treatment and prognosis for a poor vascular and functional outcome after the procedure. Amputation is also indicated in the presence of severe infection threatening the life of the patient, or when the extent of ischemic tissue necrosis of the lower extremity is such that a functional foot is no longer salvageable [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/16695.html" rel="external">"Lower extremity amputation"</a>.)</p><p class="headingAnchor" id="H684637827"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117201.html" rel="external">"Society guideline links: Occlusive carotid, aortic, renal, mesenteric, and peripheral atherosclerotic disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a>.)</p><p class="headingAnchor" id="H2566133279"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral artery disease (PAD) is more prevalent among patients with diabetes mellitus (DM) than in the general population. The clinical manifestations of PAD are largely similar in patients with and without DM. Limited data suggest that patients with DM may be more likely to be asymptomatic or have atypical symptoms leading to more severe disease at initial clinical presentation. Patients with DM also have an increased risk for limb loss. (See <a class="local">'Epidemiology and risk factors'</a> above and <a class="local">'Clinical manifestations and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our recommendations align with American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommending screening ankle-brachial index (ABI) in subjects with diabetes age 50 to 64 years or &lt;50 years and with at least one additional risk factor for atherosclerosis. Since patients with DM have an increased risk for cardiac and PAD morbidity and mortality, screening patients with DM for PAD may be considered, if therapy will be modified based on the results of the screening test. When symptoms do occur, there should be a low threshold to obtain vascular studies to evaluate for ischemia. (See <a class="local">'Screening'</a> above and  <a class="medical medical_review" href="/z/d/html/15238.html" rel="external">"Screening for lower extremity peripheral artery disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DM is an established risk factor for cardiovascular disease. As such, cardiovascular risk reduction strategies (smoking cessation, lipid-lowering therapy, antihypertensive therapy, glycemic control, diet and exercise) are recommended to reduce the risk for future cardiovascular events, including limb-related events. (See <a class="local">'Risk factor modification'</a> above and  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long term antithrombotic therapy using <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (75 to 100 mg/day) or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> (75 mg daily) is recommended for all patients with PAD, including those with DM, to reduce the risk of overall cardiovascular events and death unless contraindications exist. We do not routinely recommended dual antiplatelet therapy (DAPT) for patients with DM and PAD, unless there is a clear indication such as coronary or peripheral arterial intervention. (See <a class="local">'Antithrombotic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Indications for revascularization (ie, angioplasty/stenting, surgical bypass) for patients with DM and PAD are no different compared with the general population. The nature of the intervention may differ since the distribution of lower extremity atherosclerosis differs with patients with DM tending to have severe occlusive disease in arterial vessels below the knee. In addition, patients with DM and chronic limb-threatening ischemia may require multiple revascularization procedures to achieve outcomes comparable to patients without DM. (See <a class="local">'Revascularization'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047.</a></li><li><a class="nounderline abstract_t">Fox CS, Golden SH, Anderson C, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation 2015; 132:691.</a></li><li><a class="nounderline abstract_t">Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg 2016; 63:3S.</a></li><li><a class="nounderline abstract_t">Newman JD, Rockman CB, Kosiborod M, et al. Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease. Am Heart J 2017; 184:114.</a></li><li><a class="nounderline abstract_t">Shah B, Rockman CB, Guo Y, et al. Diabetes and vascular disease in different arterial territories. Diabetes Care 2014; 37:1636.</a></li><li><a class="nounderline abstract_t">Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population &gt;=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004; 27:1591.</a></li><li><a class="nounderline abstract_t">Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015; 116:1509.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26:3333.</a></li><li><a class="nounderline abstract_t">Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47:921.</a></li><li class="breakAll">https://www.cdc.gov/DHDSP/data_statistics/fact_sheets/fs_PAD.htm (Accessed on February 28, 2019).</li><li><a class="nounderline abstract_t">Beckman JA, Creager MA. Vascular Complications of Diabetes. Circ Res 2016; 118:1771.</a></li><li><a class="nounderline abstract_t">Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013; 34:2444.</a></li><li><a class="nounderline abstract_t">Thiruvoipati T, Kielhorn CE, Armstrong EJ. Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes 2015; 6:961.</a></li><li><a class="nounderline abstract_t">Beks PJ, Mackaay AJ, de Neeling JN, et al. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study. Diabetologia 1995; 38:86.</a></li><li><a class="nounderline abstract_t">Escobar C, Blanes I, Ruiz A, et al. Prevalence and clinical profile and management of peripheral arterial disease in elderly patients with diabetes. Eur J Intern Med 2011; 22:275.</a></li><li><a class="nounderline abstract_t">Bhandari N, Newman JD, Berger JS, Smilowitz NR. Diabetes mellitus and outcomes of lower extremity revascularization for peripheral artery disease. Eur Heart J Qual Care Clin Outcomes 2022; 8:298.</a></li><li><a class="nounderline abstract_t">Aquino R, Johnnides C, Makaroun M, et al. Natural history of claudication: long-term serial follow-up study of 1244 claudicants. J Vasc Surg 2001; 34:962.</a></li><li><a class="nounderline abstract_t">Faglia E, Clerici G, Mantero M, et al. Incidence of critical limb ischemia and amputation outcome in contralateral limb in diabetic patients hospitalized for unilateral critical limb ischemia during 1999-2003 and followed-up until 2005. Diabetes Res Clin Pract 2007; 77:445.</a></li><li><a class="nounderline abstract_t">Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001; 24:1433.</a></li><li><a class="nounderline abstract_t">Haltmayer M, Mueller T, Horvath W, et al. Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease. Int Angiol 2001; 20:200.</a></li><li><a class="nounderline abstract_t">Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382:1329.</a></li><li><a class="nounderline abstract_t">Al-Delaimy WK, Merchant AT, Rimm EB, et al. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med 2004; 116:236.</a></li><li><a class="nounderline abstract_t">Adler AI, Stevens RJ, Neil A, et al. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002; 25:894.</a></li><li><a class="nounderline abstract_t">Regensteiner JG, Golden S, Huebschmann AG, et al. Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation 2015; 132:2424.</a></li><li><a class="nounderline abstract_t">Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985; 33:13.</a></li><li><a class="nounderline abstract_t">Newman JD, Schwartzbard AZ, Weintraub HS, et al. Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. J Am Coll Cardiol 2017; 70:883.</a></li><li><a class="nounderline abstract_t">Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97:425.</a></li><li><a class="nounderline abstract_t">Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195.</a></li><li><a class="nounderline abstract_t">Donath MY, Dalmas É, Sauter NS, Böni-Schnetzler M. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab 2013; 17:860.</a></li><li><a class="nounderline abstract_t">Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82:513.</a></li><li><a class="nounderline abstract_t">Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013; 34:2436.</a></li><li><a class="nounderline abstract_t">Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106:1319.</a></li><li><a class="nounderline abstract_t">Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108:1527.</a></li><li><a class="nounderline abstract_t">Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88:E14.</a></li><li><a class="nounderline abstract_t">Allen JD, Giordano T, Kevil CG. Nitrite and nitric oxide metabolism in peripheral artery disease. Nitric Oxide 2012; 26:217.</a></li><li><a class="nounderline abstract_t">Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107:1058.</a></li><li><a class="nounderline abstract_t">Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813.</a></li><li><a class="nounderline abstract_t">Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002; 106:1783.</a></li><li><a class="nounderline abstract_t">Li H, Förstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 190:244.</a></li><li><a class="nounderline abstract_t">Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262:157.</a></li><li><a class="nounderline abstract_t">Vazzana N, Ranalli P, Cuccurullo C, Davì G. Diabetes mellitus and thrombosis. Thromb Res 2012; 129:371.</a></li><li><a class="nounderline abstract_t">Cefalu WT, Schneider DJ, Carlson HE, et al. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care 2002; 25:2123.</a></li><li><a class="nounderline abstract_t">Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 2007; 7:223.</a></li><li><a class="nounderline abstract_t">Vaidyula VR, Rao AK, Mozzoli M, et al. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006; 55:202.</a></li><li><a class="nounderline abstract_t">Sinning JM, Losch J, Walenta K, et al. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2011; 32:2034.</a></li><li><a class="nounderline abstract_t">Tsimerman G, Roguin A, Bachar A, et al. Involvement of microparticles in diabetic vascular complications. Thromb Haemost 2011; 106:310.</a></li><li><a class="nounderline abstract_t">Zeiger F, Stephan S, Hoheisel G, et al. P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis 2000; 11:723.</a></li><li><a class="nounderline abstract_t">Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24:1476.</a></li><li><a class="nounderline abstract_t">Latif KA, Freire AX, Kitabchi AE, et al. The use of alkali therapy in severe diabetic ketoacidosis. Diabetes Care 2002; 25:2113.</a></li><li><a class="nounderline abstract_t">Bird CE, Criqui MH, Fronek A, et al. Quantitative and qualitative progression of peripheral arterial disease by non-invasive testing. Vasc Med 1999; 4:15.</a></li><li><a class="nounderline abstract_t">Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012; 126:2890.</a></li><li><a class="nounderline abstract_t">Creager MA, Belkin M, Bluth EI, et al. 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to develop Clinical Data Standards for peripheral atherosclerotic vascular disease). J Am Coll Cardiol 2012; 59:294.</a></li><li><a class="nounderline abstract_t">Aboyans V, Ho E, Denenberg JO, et al. The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects. J Vasc Surg 2008; 48:1197.</a></li><li><a class="nounderline abstract_t">Suominen V, Rantanen T, Venermo M, et al. Prevalence and risk factors of PAD among patients with elevated ABI. Eur J Vasc Endovasc Surg 2008; 35:709.</a></li><li><a class="nounderline abstract_t">Wang JC, Criqui MH, Denenberg JO, et al. Exertional leg pain in patients with and without peripheral arterial disease. Circulation 2005; 112:3501.</a></li><li><a class="nounderline abstract_t">Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014; 59:220.</a></li><li><a class="nounderline abstract_t">Ferket BS, Spronk S, Colkesen EB, Hunink MG. Systematic review of guidelines on peripheral artery disease screening. Am J Med 2012; 125:198.</a></li><li><a class="nounderline abstract_t">Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 69:e71.</a></li><li><a class="nounderline abstract_t">Wilcox T, Newman JD, Maldonado TS, et al. Peripheral vascular disease risk in diabetic individuals without coronary heart disease. Atherosclerosis 2018; 275:419.</a></li><li><a class="nounderline abstract_t">Olin JW, Halperin JL. US Preventive Services Task Force recommendation statement regarding screening for peripheral artery disease with the ankle-brachial index: déjà vu all over again. Lancet 2018; 392:1160.</a></li><li><a class="nounderline abstract_t">Beckman JA. The U.S. Preventive Services Task Force - Objectivity as Authority. J Am Coll Cardiol 2019; 73.</a></li><li><a class="nounderline abstract_t">Moyer VA, U.S. Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159:342.</a></li><li><a class="nounderline abstract_t">National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.</a></li><li><a class="nounderline abstract_t">Jones WS, Baumgartner I, Hiatt WR, et al. Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. Circulation 2017; 135:241.</a></li><li><a class="nounderline abstract_t">Low Wang CC, Blomster JI, Heizer G, et al. Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. J Am Coll Cardiol 2018; 72:3274.</a></li><li><a class="nounderline abstract_t">Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004; 40:1158.</a></li><li><a class="nounderline abstract_t">Rea TD, Heckbert SR, Kaplan RC, et al. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002; 137:494.</a></li><li><a class="nounderline abstract_t">Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 2013; 309:1014.</a></li><li><a class="nounderline abstract_t">Hennrikus D, Joseph AM, Lando HA, et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol 2010; 56:2105.</a></li><li><a class="nounderline abstract_t">Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014; 129:28.</a></li><li><a class="nounderline abstract_t">Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344:e2856.</a></li><li><a class="nounderline abstract_t">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.</a></li><li><a class="nounderline abstract_t">Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301:1909.</a></li><li><a class="nounderline abstract_t">Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.</a></li><li><a class="nounderline abstract_t">Critical Leg Ischaemia Prevention Study (CLIPS) Group, Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007; 261:276.</a></li><li><a class="nounderline abstract_t">CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90:625.</a></li><li><a class="nounderline abstract_t">Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372:1791.</a></li><li><a class="nounderline abstract_t">Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol 2016; 67:2719.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol 2016; 67:2732.</a></li><li><a class="nounderline abstract_t">Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med 2019; 381:1309.</a></li><li><a class="nounderline abstract_t">Vorapaxar. Am J Cardiovasc Drugs 2010; 10:413.</a></li><li><a class="nounderline abstract_t">Bonaca MP, Gutierrez JA, Creager MA, et al. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation 2016; 133:997.</a></li><li><a class="nounderline abstract_t">Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366:1404.</a></li><li><a class="nounderline abstract_t">Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation 2013; 127:1522.</a></li><li><a class="nounderline abstract_t">Cavender MA, Scirica BM, Bonaca MP, et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation 2015; 131:1047.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377:1319.</a></li><li><a class="nounderline abstract_t">Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391:219.</a></li><li><a class="nounderline abstract_t">Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357:217.</a></li><li><a class="nounderline abstract_t">Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med 2020; 382:1994.</a></li><li><a class="nounderline abstract_t">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S1.</a></li><li><a class="nounderline abstract_t">Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45:645.</a></li><li><a class="nounderline abstract_t">Arya S, Khakharia A, Binney ZO, et al. Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease. Circulation 2018; 137:1435.</a></li><li><a class="nounderline abstract_t">O'Donnell TFX, Deery SE, Darling JD, et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. J Vasc Surg 2017; 66:572.</a></li><li><a class="nounderline abstract_t">Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117.</a></li><li><a class="nounderline abstract_t">Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29:1220.</a></li><li><a class="nounderline abstract_t">Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29:1478.</a></li><li><a class="nounderline abstract_t">Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2018; 137:338.</a></li><li><a class="nounderline abstract_t">Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376:1713.</a></li><li><a class="nounderline abstract_t">Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373:1780.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care 2016; 39 Suppl 1:S13.</a></li><li><a class="nounderline abstract_t">Cameron-Vendrig A, Reheman A, Siraj MA, et al. Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. Diabetes 2016; 65:1714.</a></li><li><a class="nounderline abstract_t">Barale C, Buracco S, Cavalot F, et al. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. Thromb Haemost 2017; 117:1115.</a></li><li><a class="nounderline abstract_t">Rakipovski G, Rolin B, Nøhr J, et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci 2018; 3:844.</a></li><li><a class="nounderline abstract_t">Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373:2117.</a></li><li><a class="nounderline abstract_t">Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377:644.</a></li><li><a class="nounderline abstract_t">Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375:311.</a></li><li><a class="nounderline abstract_t">Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375:1834.</a></li><li><a class="nounderline abstract_t">Bethel MA, McMurray JJV. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist. Circulation 2018; 137:1218.</a></li><li><a class="nounderline abstract_t">Udell JA, Yuan Z, Rush T, et al. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Circulation 2018; 137:1450.</a></li><li><a class="nounderline abstract_t">Udell JA, Morrow DA, Jarolim P, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol 2014; 63:2421.</a></li><li><a class="nounderline abstract_t">Bonaca MP, Beckman JA. Sodium Glucose Cotransporter 2 Inhibitors and Amputation Risk: Achilles' Heel or Opportunity for Discovery? Circulation 2018; 137:1460.</a></li><li><a class="nounderline abstract_t">Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380:2295.</a></li><li><a class="nounderline abstract_t">Verma S, Mazer CD, Al-Omran M, et al. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. Circulation 2018; 137:405.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380:347.</a></li><li><a class="nounderline abstract_t">Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation 2020; 142:734.</a></li><li><a class="nounderline abstract_t">Dhatariya K, Bain SC, Buse JB, et al. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care 2018; 41:2229.</a></li><li><a class="nounderline abstract_t">Verma S, Al-Omran M, Leiter LA, et al. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab 2022; 24:1288.</a></li><li><a class="nounderline abstract_t">Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373:2247.</a></li><li><a class="nounderline abstract_t">Badjatiya A, Merrill P, Buse JB, et al. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. Circ Cardiovasc Interv 2019; 12:e008018.</a></li><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71:2199.</a></li><li><a class="nounderline abstract_t">Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens 2011; 29:1448.</a></li><li><a class="nounderline abstract_t">Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev 2013; :CD005508.</a></li><li><a class="nounderline abstract_t">ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.</a></li><li><a class="nounderline abstract_t">Skrepnek GH, Armstrong DG, Mills JL. Open bypass and endovascular procedures among diabetic foot ulcer cases in the United States from 2001 to 2010. J Vasc Surg 2014; 60:1255.</a></li><li><a class="nounderline abstract_t">Akbari CM, Pomposelli FB Jr, Gibbons GW, et al. Lower extremity revascularization in diabetes: late observations. Arch Surg 2000; 135:452.</a></li><li><a class="nounderline abstract_t">Albers M, Romiti M, Brochado-Neto FC, et al. Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. J Vasc Surg 2006; 43:498.</a></li><li><a class="nounderline abstract_t">Mills JL. Lower limb ischaemia in patients with diabetic foot ulcers and gangrene: recognition, anatomic patterns and revascularization strategies. Diabetes Metab Res Rev 2016; 32 Suppl 1:239.</a></li><li><a class="nounderline abstract_t">Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287:2570.</a></li><li><a class="nounderline abstract_t">Faries PL, LoGerfo FW, Hook SC, et al. The impact of diabetes on arterial reconstructions for multilevel arterial occlusive disease. Am J Surg 2001; 181:251.</a></li><li><a class="nounderline abstract_t">Panneton JM, Gloviczki P, Bower TC, et al. Pedal bypass for limb salvage: impact of diabetes on long-term outcome. Ann Vasc Surg 2000; 14:640.</a></li><li><a class="nounderline abstract_t">Stokes KR, Strunk HM, Campbell DR, et al. Five-year results of iliac and femoropopliteal angioplasty in diabetic patients. Radiology 1990; 174:977.</a></li><li><a class="nounderline abstract_t">Singh S, Armstrong EJ, Sherif W, et al. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty. Vasc Med 2014; 19:307.</a></li><li><a class="nounderline abstract_t">Dick F, Diehm N, Galimanis A, et al. Surgical or endovascular revascularization in patients with critical limb ischemia: influence of diabetes mellitus on clinical outcome. J Vasc Surg 2007; 45:751.</a></li><li><a class="nounderline abstract_t">Awad S, Karkos CD, Serrachino-Inglott F, et al. The impact of diabetes on current revascularisation practice and clinical outcome in patients with critical lower limb ischaemia. Eur J Vasc Endovasc Surg 2006; 32:51.</a></li></ol></div><div id="topicVersionRevision">Topic 17035 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111519" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26246173" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26804367" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28224925" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705616" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diabetes and vascular disease in different arterial territories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220233" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of lower-extremity disease in the US adult population&gt;=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25908725" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633825" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Peripheral arterial disease in people with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16516072" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Peripheral arterial disease in patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16516072" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Peripheral arterial disease in patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27230641" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Vascular Complications of Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23625211" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26185603" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7744233" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21570647" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence and clinical profile and management of peripheral arterial disease in elderly patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33351089" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diabetes mellitus and outcomes of lower extremity revascularization for peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11743546" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Natural history of claudication: long-term serial follow-up study of 1244 claudicants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17316866" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence of critical limb ischemia and amputation outcome in contralateral limb in diabetic patients hospitalized for unilateral critical limb ischemia during 1999-2003 and followed-up until 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11473082" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11573053" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23915883" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14969651" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978687" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26644329" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3965550" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Update on some epidemiologic features of intermittent claudication: the Framingham Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28797359" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Primary Prevention of Cardiovascular Disease in Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9490235" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18997196" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23747245" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8329706" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23641007" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20431074" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Activation of protein kinase C isoforms and its impact on diabetic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504252" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157681" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mechanisms underlying endothelial dysfunction in diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22426034" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nitrite and nitric oxide metabolism in peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030723" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Oxidative stress and diabetic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11742414" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Biochemistry and molecular cell biology of diabetic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12356630" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Increased activity of endogenous endothelin in patients with type II diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10685059" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Nitric oxide in the pathogenesis of vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17645584" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Diabetes mellitus as a prothrombotic condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22197180" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diabetes mellitus and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12453948" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17547839" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380494" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21186238" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713319" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Involvement of microparticles in diabetic vascular complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11132650" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11473089" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Platelet dysfunction in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401775" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The use of alkali therapy in severe diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10355865" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Quantitative and qualitative progression of peripheral arterial disease by non-invasive testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23159553" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22153885" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to develop Clinical Data Standards for peripheral atherosclerotic vascular disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18692981" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18313338" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prevalence and risk factors of PAD among patients with elevated ABI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16316971" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Exertional leg pain in patients with and without peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126108" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22079018" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Systematic review of guidelines on peripheral artery disease screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27851992" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29801688" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Peripheral vascular disease risk in diabetic individuals without coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30303084" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : US Preventive Services Task Force recommendation statement regarding screening for peripheral artery disease with the ankle-brachial index: déjàvu all over again.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The U.S. Preventive Services Task Force - Objectivity as Authority</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026320" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12485966" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27840336" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30573030" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15622370" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Influence of smoking on incidence and prevalence of peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12230350" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Smoking status and risk for recurrent coronary events after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23483176" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21144971" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24323793" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22563098" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786451" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436018" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18927173" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17305650" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918275" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12231089" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25773268" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Long-term use of ticagrelor in patients with prior myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27046162" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27046160" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31475798" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Ticagrelor in Patients with Stable Coronary Disease and Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21090833" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Vorapaxar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26826179" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22443427" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Vorapaxar in the secondary prevention of atherothrombotic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23501976" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25681464" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844192" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29132880" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634457" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222135" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Rivaroxaban in Peripheral Artery Disease after Revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222016" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17398372" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29330214" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28506476" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191683" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731999" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801565" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133605" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28304224" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19465233" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26696675" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : 2. Classification and Diagnosis of Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26936963" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28405672" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30623143" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26378978" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605608" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27295427" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27633186" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29555706" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133607" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24727254" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610127" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Sodium Glucose Cotransporter 2 Inhibitors and Amputation Risk: Achilles' Heel or Opportunity for Discovery?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30990260" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133602" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415602" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32795086" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30072400" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35332654" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630143" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31752517" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29146533" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21602713" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24027118" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Beta blockers for peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378520" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Telmisartan, ramipril, or both in patients at high risk for vascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25017514" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Open bypass and endovascular procedures among diabetic foot ulcer cases in the United States from 2001 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10768711" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Lower extremity revascularization in diabetes: late observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16520163" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26455728" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Lower limb ischaemia in patients with diabetic foot ulcers and gangrene: recognition, anatomic patterns and revascularization strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020339" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11376581" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : The impact of diabetes on arterial reconstructions for multilevel arterial occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11128460" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Pedal bypass for limb salvage: impact of diabetes on long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137639" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Five-year results of iliac and femoropopliteal angioplasty in diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24939930" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17306950" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Surgical or endovascular revascularization in patients with critical limb ischemia: influence of diabetes mellitus on clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488631" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : The impact of diabetes on current revascularisation practice and clinical outcome in patients with critical lower limb ischaemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
